HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
While originally thought to be a serine protease, OmpT is better characterized as an aspartyl protease because of its cleavage mechanism. The substrate of OmpT binds to negatively charged aspartate and glutamate residues, so the active site of the protease is anionic. This causes OmpT to selectively cleave peptides between two basic (positively charged) residues. The active site of OmpT resembles that of other omptins, and is characterized by conserved residues at Asp84, Asp86, Asp206, and His208. The most common bond cleavage by OmpT is between two arginine residues because their positive charge can favorably interact with the negatively charged species at the active site during substrate binding. Because of the specificity of the active site, OmpT does not act on peptides with a negatively charged residue adjacent to the scissile bond. Also, OmpT is specifically identified an endopeptidase because it does not cleave peptides at the N- or C-terminus, but only between nonterminal amino acids. The peptide bond cleavage occurs via the nucleophilic attack of water at the carbonyl between two adjacent amino acid residues. Water enters the protease from the intracellular surface and is stabilized by Asp83 and His212. During the proton transfer associated with the peptide cleavage, the negatively charged aspartate residue stabilizes the positively charged histidine. Once docked in this position, water is positioned to attack the peptide in the active site. The cleavage of peptide bonds by OmpT is also dependent on the presence of bound lipopolysaccharide (LPS).
=== Atomic radius === Historically, the physical size of atoms was unknown until the early 20th century. The first calculated estimate of the atomic radius of hydrogen was published by physicist Arthur Haas in 1910 to within an order of magnitude (a factor of 10) of the accepted value, the Bohr radius (~0.529 Å). In his model, Haas used a single-electron configuration based on the classical atomic model proposed by J. J. Thomson in 1904, often called the plum-pudding model. Atomic radii (the size of atoms) are dependent on the sizes of their outermost orbitals. They generally decrease going left to right along the main-group elements, because the nuclear charge increases but the outer electrons are still in the same shell. However, going down a column, the radii generally increase, because the outermost electrons are in higher shells that are thus further away from the nucleus. The first row of each block is abnormally small, due to an effect called kainosymmetry or primogenic repulsion: the 1s, 2p, 3d, and 4f subshells have no inner analogues. For example, the 2p orbitals do not experience strong repulsion from the 1s and 2s orbitals, which have quite different angular charge distributions, and hence are not very large; but the 3p orbitals experience strong repulsion from the 2p orbitals, which have similar angular charge distributions. Thus higher s-, p-, d-, and f-subshells experience strong repulsion from their inner analogues, which have approximately the same angular distribution of charge, and must expand to avoid this.
The preparation of other cuprates is more difficult than the YBCO preparation. They also have a different crystal structure: they are tetragonal where YBCO is orthorhombic. Problems in these superconductors arise because of the existence of three or more phases having a similar layered structure. Moreover, the crystal structure of other tested cuprate superconductors are very similar. Like YBCO, the perovskite-type feature and the presence of simple copper oxide (CuO2) layers also exist in these superconductors. However, unlike YBCO, Cu–O chains are not present in these superconductors. The YBCO superconductor has an orthorhombic structure, whereas the other high-Tc superconductors have a tetragonal structure. There are three main classes of superconducting cuprates: bismuth-based, thallium-based and mercury-based. The second cuprate by practical importance is currently BSCCO, a compound of Bi–Sr–Ca–Cu–O. The content of bismuth and strontium creates some chemical issues. It has three superconducting phases forming a homologous series as Bi2Sr2Can−1CunO4+2n+x (n=1, 2 and 3). These three phases are Bi-2201, Bi-2212 and Bi-2223, having transition temperatures of 20 K (−253.2 °C), 85 K (−188.2 °C) and 110 K (−163 °C), respectively, where the numbering system represent number of atoms for Bi Sr, Ca and Cu respectively. The two phases have a tetragonal structure which consists of two sheared crystallographic unit cells.
Sources: en.wikipedia.org
Only once, when she was 13, did she make an extended visit to her parents, then living in Khartoum, the capital of Sudan, where her father was Principal of Gordon College. When she was 14, her distant cousin, the chemist Charles Harington (later Sir Charles), recommended D. S. Parsons' Fundamentals of Biochemistry. Resuming the pre-war pattern, her parents lived and worked abroad for part of the year, returning to England and their children for several months every summer. In 1926, on his retirement from the Sudan Civil Service, her father took the post of Director of the British School of Archaeology in Jerusalem, where he and her mother remained until 1935. In 1928, Hodgkin joined her parents at the archaeological site of Jerash, in present-day Jordan, where she documented the patterns of mosaics from multiple Byzantine-era Churches dated to the 5th–6th centuries. She spent more than a year finishing the drawings as she started her studies in Oxford, while also conducting chemical analyses of glass tesserae from the same site. Her attention to detail through the creation of precise scale drawings of these mosaics mirrors her subsequent work in recognising and documenting patterns in chemistry. Hodgkin enjoyed the experience of field archaeology so much that she considered giving up chemistry in favour of archaeology. Her drawings are archived by Yale University. Hodgkin developed a passion for chemistry from a young age, and her mother, a proficient botanist, fostered her interest in the sciences. On her 16th birthday her mother gave her a book by W. H.
On 16 December 1944, the Germans launched a surprise offensive through the Ardennes Forest, which became known as the Battle of the Bulge. In SHAEF reserve, the 82nd was committed on the northern face of the bulge near Elsenborn Ridge. On 20 December 1944, the 82nd Airborne Division was assigned to take Cheneux which had been captured by Kampfgruppe Peiper. On 21–22 December 1944, the 82nd Airborne faced counterattacks from two Waffen SS divisions which included the 1st SS Panzer Division Leibstandarte SS Adolf Hitler (lit. translation "The SS Bodyguard Division of Adolf Hitler") and the 9th SS Panzer Division Hohenstaufen. The Waffen SS efforts to relieve the Kampfgruppe Peiper failed due to the stubborn defense of the 82nd Airborne, the 30th ID, 2nd ID, and other units. On December 23, German forces launched an attack from the south, overrunning elements of the 325th Glider Infantry Regiment at the Baraque-Fraiture crossroads. This maneuver compromised the southern flank of the 82nd Airborne Division. The objective of the 2nd SS Panzer Division Das Reich was to outflank the 82nd Airborne Division rather than to directly link up with the isolated Kampfgruppe Peiper further north. However, a successful encirclement could have opened a corridor to reach the cut-off armored unit. The German offensive failed to achieve this breakthrough before American reinforcements stabilized the perimeter.
Melanin produced by plants are sometimes referred to as 'catechol melanins' as they can yield catechol on alkali fusion. It is commonly seen in the enzymatic browning of fruits such as bananas. Chestnut shell melanin can be used as an antioxidant and coloring agent. Biosynthesis involves the oxidation of indole-5,6-quinone by the tyrosinase type polyphenol oxidase from tyrosine and catecholamines leading to the formation of catechol melanin. Despite this many plants contain compounds which inhibit the production of melanins.
== Sources == MCD peptide is a component of bumblebee (Megabombus pennsylvanicus) venom. In addition to MCD peptide, melittin and apamin have also been identified in this venom and are also described as voltage-dependent channel blockers. MCD peptide is also present in the venom of the honey bee Apis mellifera.
Sources: en.wikipedia.org
=== Carcinogenicity === The National Toxicology Program from the Department of Health and Human Services published the Fifteenth Edition Report on Carcinogens, which stated that BaP caused tumors in 8 species, including nonhuman primates.
genetic code A set of rules by which information encoded within nucleic acids is translated into proteins by living cells. These rules define how sequences of three consecutive nucleotides called codons specify which amino acid will be added next during protein synthesis. The vast majority of living organisms use the same genetic code (sometimes referred to as the "standard" genetic code) but variant codes do exist.
The lengthy volume that emerged contained a diverse collection of opinions, with some stating the South Vietnamese were making "rapid strides," while others doubted that the government in Saigon would "ever constitute an effective political or military counter to the Vietcong". The "bulls" estimated that American troops would need to fight on in Vietnam for 8.3 years before the South Vietnamese would be able to fight on their own while the "bears" estimated it would take 13.4 years of American troops fighting in Vietnam before the South Vietnamese would be able to fight on their own. Kissinger passed the volume on to Nixon with the comment that there was no consensus within the expert community with the implied conclusion that he should be free to act on his own without consulting the experts.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.